How long does a Mounjaro approval last with Florida Blue?

Type 2 Diabetes — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months.

What does Florida Blue require to renew Mounjaro?

Type 2 Diabetes — Applies to Employer plans. Eligible for continuation if patient has been treated with a preferred agent (Ozempic, Rybelsus, Trulicity, Mounjaro, or Bydureon BCise) within the past 90 days and prescriber confirms treatment or states patient is at risk if preferred agent is discontinued. Starting on samples is not approvable.

How current is this information?

The oldest review date among the policies on this page is June 5, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Does Florida Blue cover Mounjaro?

Applies to Employer plans.

Covered (preferred drug)

Qualification pathways

You can qualify through any one of these.

Continuation of therapy (Mounjaro as preferred)

All of:

Diagnosis of type 2 diabetes mellitus (medical record documentation required)
Mounjaro is eligible for continuation of therapy
Patient will NOT use requested agent in combination with a DPP-4 containing agent
Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications to the requested agent
Request is NOT for weight loss (weight loss is a benefit exclusion)

Plus any one of:

Patient has been treated with a preferred agent within the past 90 days (starting on samples is not approvable)
Prescriber states patient has been treated with a preferred agent within the past 90 days and patient is at risk if therapy with a preferred agent is discontinued

New/initial therapy as preferred agent

All of:

Diagnosis of type 2 diabetes mellitus (medical record documentation required)
Requested agent is a preferred agent (Mounjaro qualifies)
Patient's age is within FDA labeling for the requested indication OR there is support for using the requested agent for the patient's age
Patient will NOT use requested agent in combination with a DPP-4 containing agent
Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications to the requested agent
Request is NOT for weight loss (weight loss is a benefit exclusion)

Documentation to bring

Medical record documentation of type 2 diabetes mellitus diagnosis
If continuation: documentation of prior preferred agent use within past 90 days (paid claim from another health plan within past 90 days is acceptable alternative to step therapy requirement)
If non-preferred step therapy: medical record documentation of intolerance/contraindication to preferred agents (two of: semaglutide, dulaglutide, tirzepatide)
Documentation that patient will not be using agent in combination with a DPP-4 inhibitor
Documentation that patient will not be using agent in combination with another GLP-1 receptor agonist
Confirmation that request is not for weight loss

Quantity limits

2.5 mg/0.5 mL — 4 pens
5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL — 4 pens

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
Renewal: Eligible for continuation if patient has been treated with a preferred agent (Ozempic, Rybelsus, Trulicity, Mounjaro, or Bydureon BCise) within the past 90 days and prescriber confirms treatment or states patient is at risk if preferred agent is discontinued. Starting on samples is not approvable.

Not covered when

Combination with DPP-4 inhibitors not permitted
Combination with another GLP-1 receptor agonist not permitted
FDA labeled contraindications apply
Starting on samples is not approvable for continuation pathway
Weight loss use is a benefit exclusion
Fill limit: one GLP-1 agent and one strength per 28 days
2.5 mg strength must NOT be used for maintenance therapy (initiation/induction only)

Policy note: Mounjaro is listed as a preferred agent. Non-preferred agents (Byetta, Exenatide, Victoza) require two of the following prior preferred agent trials/failures: semaglutide (Ozempic or Rybelsus), dulaglutide (Trulicity), or tirzepatide (Mounjaro). Mounjaro is approved for T2DM in adults and pediatric patients 10 years and older per FDA labeling. Step therapy requirement may not apply if the requested medication was previously approved by another health plan and documentation of a paid claim within the past 90 days is submitted. Quantity limit override available for dose exceeding program QL with clinical justification including diagnosis of T2DM, dose does not exceed FDA maximum labeled dose, or support for higher dose. Fill limit override for switching GLP-1 agents/strengths is a one-time approval with a 6-month lockout for prior fill limit overrides.

Policy effective May 11, 2026 · verified June 5, 2026 · source: Fl GLP-1 Paql Prog Sum · View policy document (PDF)